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A B S T R A C T
Well-defined, heterotelechelic polymer prodrugs for combination therapy were synthesized by using a combi-
nation of the “drug-initiated” nitroxide-mediated polymerization from a gemcitabine-alkoxyamine initiator and
the nitroxide exchange reaction using TEMPO-bearing drugs to end-cap the drug-polymer chain-end by a second
drug. This methodology was successfully applied to two different clinically relevant combinations, gemcitabine/
doxorubicin (Gem/Dox) and gemcitabine/lapatinib (Gem/Lap), showing a certain degree of universality of the
synthetic methodology. It also represented the first nanocarrier for the co-delivery of Gem and Lap ever reported.
Well-controlled, low molar mass heterotelechelic polymers (Mn= 2100–4090 g.mol−1, Ð=1.18–1.38) with
~1:1 drug ratios and high overall drug loadings up to 40 wt% were obtained. They were formulated into na-
noparticles by nanoprecipitation and exhibited average diameters in the 34–154 nm range, with narrow particle
size distributions (PSD=0.01–0.22) and excellent colloidal stability over time. Their biological evaluation in
terms of drug release and cytotoxicity was performed and compared to that of different monofunctional polymer
prodrug formulations. We showed that heterobifunctional polymer prodrugs induced cytotoxicity to MCF-7 cells,
with IC50 values in the 120–300 nM range depending on the combination tested. Interestingly, whereas Gem/
Dox combination did not lead to noticeable improvement over monofunctional therapies, co-nanoprecipitation
of Gem/Lap prodrugs led to synergistic effect.
1. Introduction
Combination therapy refers to the simultaneous administration of
two or more pharmaceutical agents and has shown clear therapeutic
benefits to treat different diseases, such as malaria [1,2], HIV [3,4] and
cancer [5,6]. Combination therapy offers important advantages com-
pared to monotherapy such as the possibility to modulate different
signaling pathways by using drugs with different/complementary me-
chanisms of actions, which may lead to synergistic effect, and the
possibility to overcome resistance mechanisms. For these reasons,
combination therapy is commonly associated with improved ther-
apeutic indexes and better long-term prognosis, thanks to enhanced
efficacy and/or reduction of the dose of each drug, resulting in less
severe side effects and toxicity, which is of prime importance for in-
stance in cancer therapy [7,8].
The main limitation of this approach, however, is that biodistribu-
tions and pharmacokinetics can greatly vary from one drug to another,
for instance because each drug may have different physico-chemical
properties, hydrolytic stabilities, metabolizations, etc. Therefore, pre-
cisely controlling the drug ratio until delivery to the right tissues and
cells is challenging. To overcome this problem, drugs can be formulated
into the same nanocarrier, such as liposomes or polymer nanoparticles,
which is expected to maintain the initial drug ratio until cellular in-
ternalization [6–9]. However, the traditional encapsulation of drugs
into nanocarriers is often associated with important limitations such as
the “burst release”, referring to the quick and sudden release post-ad-
ministration of a significant amount of drug only surface-adsorbed,
which may induce prohibitive toxicity but also strongly vary the drug
ratios and the effective drug loading (DL). Also, poor DLs are generally
obtained which imposes administration of large amounts of
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nanocarriers to achieve a therapeutic effect. The “polymer prodrug”
approach [10,11], whereby the drug is covalently attached to the
polymer carrier, aims to solve these limitations. Among the different
synthetic pathways to synthesize polymer prodrugs, the recently de-
veloped “drug-initiated” method [12], relying on the controlled growth
of a small polymer chain from a drug-bearing initiator, have indis-
putable advantages compared to other approaches, such as: (i) a few
synthetic steps with high overall yields and reproducibility; (ii) sim-
plified purification procedures; (iii) quantitative functionalization of
each polymer chain and (iv) the possibility to tune the DL due to con-
trolled polymerization process and obtain high DLs by targeting short
polymer chains.
This technique has been recently applied to different anticancer
drugs such as gemcitabine (Gem) [13–16], paclitaxel [17–19] and
cladribine [20,21], by reversible-deactivation radical polymerization
(RDRP), in particular reversible addition-fragmentation chain transfer
(RAFT) polymerization [22] and nitroxide-mediated polymerization
(NMP) [23]. In all cases, high drug loading polymer prodrug nano-
particles (up to ~40wt%) were formulated by nanoprecipitation
without any additional surfactant and showed high colloidal stability,
significant in vitro cytotoxicity against cancer cells and in vivo efficacy
on tumor-bearing mice. Also, different polymers were grown from
drugs including polyisoprene [13,17,20], chosen for its biocompat-
ibility and structural similarity with natural terpenoids [24–28], oligo
(ethylene glycol) methacrylate [17,21] for its biocompatibility and
long-circulating features, and degradable copolymers made by radical
ring-opening polymerization [16].
Recently, we proposed a facile synthetic strategy to prepare het-
erotelechelic polymer prodrugs, embedding two different molecules of
interest at both chain-ends and further self-assemble into nanoparticles
[29]. The construction methodology relied on the “drug-initiated”
synthesis of α-functional polymer prodrugs by NMP and subsequent
nitroxide exchange reaction [30] to replace the terminal nitroxide by a
functional nitroxide bearing the second molecule of interest (Fig. 1a).
As proof of concept, we synthesized heterotelechelic polymer prodrugs
based on polyisoprene, with either one drug (Gem) and one fluorescent
probe (rhodamine) for drug delivery and imaging, either two different
drugs (aminoglutethimide and doxorubicin) for combination therapy.
The latter heterotelechelic polymer prodrug was formulated into na-
noparticles that exhibited lower IC50 values than monofunctional
counterparts or nanoparticles obtained from the co-nanoprecipitation
of the two monofunctional prodrugs [29], in agreement with literature
data [31,32]. Although this synthetic methodology appeared to exhibit
important benefits, its robustness and versatility, and therefore its
future potential in the field of drug delivery, mainly depend on whether
it is applicable to other relevant drug combinations.
Herein, because heterotelechelic polymers represent original con-
structions that could be of great importance in the biomedical field
[33], we demonstrate the broad applicability and a certain degree of
universality of the “drug-initiated” method followed by the nitroxide
exchange reaction, by applying it to two different drug combinations of
high clinical interest (Fig. 1b): gemcitabine/doxorubicin (Gem/Dox)
and gemcitabine/lapatinib (Gem/Lap). Gem is used for the treatment of
many solid tumors, such as breast, lung, ovarian and pancreatic cancer
[34]. Designing Gem-based prodrugs is particularly relevant because of
the very short plasma half-life (8–17min) of Gem due to rapid meta-
bolization by deaminases [35], induction of severe side effects and
appearance of resistance mechanism associated with nucleoside trans-
membrane transporter [36]. Dox is another extensively used anticancer
drug with high efficacy against a wide array of solid tumors such as
lung, breast, ovary and thyroid cancers [37]. As for Lap, it is a dual
tyrosine kinase inhibitor, able to bind and inhibit epidermal growth
factor receptors 1 (EGFR) and 2 (HER2) [38], overexpressed in a variety
of cancer type. Nonetheless, it has very poor water solubility, which can
be greatly enhanced by formulation into nanocarriers [39–41].
Combination of free Gem and Dox has shown enhanced anticancer
efficacy compared to individual monotherapies [42–47], although se-
vere toxicity has been observed in some cases [48–50]. Therefore,
polymer-based nanocarriers based on this combination have been re-
ported. For instance, poly(N-(2-hydroxypropyl)methacrylamide)
(PHPMA) bearing both drugs grafted on the side-chain showed pro-
mising in vitro cytotoxicity and in vivo efficacy, although the drug
loading was rather modest (~6wt% for each drug) [51]. On the other
hand, poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA) diblock
copolymers were used to either prepare mixed polymer prodrugs na-
noparticles with each drug molecule linked to one PLA chain-end
(maximum drug loading was ~7wt%) [52], or PEG-b-PLA polymer-
somes encapsulating both drugs [53]. As for the second combination,
we investigated Lap that has recently been approved by the FDA in
combination with capecitabin against advanced breast cancer [54–56].
It is capable of reverting some resistance mechanisms and enhancing
other drugs' efficacy when co-administered with them [57,58]. The
safety of its combination with Gem has been demonstrated in phase I
clinical trials [59–62] and more advanced clinical studies demonstrated
good response [63] or even complete tumor remission [64]. Still, some
concerns about toxicity have been raised [65,66]. To the best of our
knowledge, this drug combination has never been delivered using na-
nocarriers, which could be a way to solve these toxicity issues.
Fig. 1. (a) Synthesis of heterobifunctional polymer prodrugs by “drug-initiated” synthesis of polymer prodrugs followed by the nitroxide exchange reaction using a
functional nitroxide. (b) Heterotelechelic polymer prodrug bearing either Gem/Dox or Gem/Lap combination.
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Importantly, it is also admitted that in the case of a multidrug ap-
proach, the way each drug is incorporated into a nanocarrier is crucial
for the drug release, the activity and the overall benefit of the combi-
nation [20,31,51,67,68]. Therefore, different drug-polymer linkers
were tested and a comprehensive investigation of the different ways to
deliver these combinations was investigated. In particular, we devel-
oped and compared: (i) heterotelechelic polymer prodrug nanoparticles
(i.e., bearing both drugs on the same polymer backbone); (ii) polymer
prodrug nanoparticles obtained by the co-nanoprecitation of the two
monofunctional polymer prodrugs (i.e., each nanoparticle is carrying
both types of polymer prodrugs) and (iii) the physical mixture of the
two monofunctional polymer prodrug nanoparticles (i.e., each nano-
particle is carrying one type of polymer prodrug) (Fig. 2).
2. Materials and methods
2.1. Materials
Gemcitabine (> 98%), lapatinib (Lap, 99%) and doxorubicin·HCl
(Dox, 99%) were purchased from Carbosynth Limited (UK).
Benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate
(PyBOP), N,N-diisopropylethylamine (DIPEA), isoprene, 4-(dimethyla-
mino)pyridine (DMAP), succinic anhydride, diglycolic anhydride, trie-
thyl amine, 4-hydroxy-TEMPO, 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU),
human serum (H4522) were purchased from Sigma-Aldrich (France)
and used as received. AMA-SG1 [69] and Gem-AMA-SG1 [13] alkox-
yamines, as well as succinic-TEMPO and TEMPO-Dox [29] were pre-
pared as reported previously. All other reactants were purchased from
Sigma-Aldrich at the highest available purity and used as received.
Deuterated chloroform (CDCl3) was obtained from Eurisotop. All other
solvents were purchased from Carlo-Erba at the highest grade. Eagle's
Minimum Essential Medium (EMEM) and fetal bovine serum (FBS) were
purchased from Dulbecco (Invitrogen, France). Penicillin and strepto-
mycin were obtained from Lonza (Verviers, Belgium). N-tert-butyl-N-
(1-diethylphosphono-2,2-dimethylpropyl) nitroxide (SG1, 85%) was
kindly supplied by Arkema.
2.2. Analytical methods
2.2.1. Nuclear magnetic resonance spectroscopy (NMR)
NMR spectroscopy was performed in 5mm diameter tubes in CDCl3
at 25 °C. 1H and 13C NMR spectroscopy was performed on a Bruker
Avance 300 spectrometer at 300MHz (1H) and 75MHz (13C), respec-
tively. The chemical shift scale was calibrated based on the internal
solvent signals. To characterize nitroxide derivatives, penta-
fluorophenylhydrazine was added in situ and allowed to react before
the analysis [70,71].
2.2.2. Mass spectrometry
Mass spectra were recorded with a Bruker Esquire-LC instrument.
High-resolution mass spectra (ESI) were recorded on an ESI/TOF (LCT,
Waters) LC-spectrometer.
2.2.3. Size exclusion chromatography (SEC)
SEC was performed at 30 °C with two columns from Polymer
Laboratories (PL-gel MIXED-D; 300×7.5mm; bead diameter 5mm;
linear part 400 to 4×105 g.mol−1), a differential refractive index de-
tector (Spectra System RI-150 from Thermo Electron Corp.) and a
scanning fluorescence detector (Waters 474). The eluent was chloro-
form at a flow rate of 1mL.min−1 (Waters 515 pump) and toluene was
used as a flow-rate marker. The calibration curve was based on poly-
styrene (PS) standards (peak molar masses,
Mp= 162–523,000 g.mol−1) from Polymer Laboratories. A poly-
isoprene (PI) calibration curve was constructed by converting the PS
standard peak molecular weights (MPS) to PI molecular weights (MPI)
using Mark-Houwink-Sakurada (MHS) constants determined for both
polymers in CCl4 at 25 °C. For PI, the MHS constants used were
KPI= 2.44×104 and αPI= 0.712. For PS, KPS= 7.1×104 and
αPS= 0.54 (Mw < 16,700 g.mol−1) or KPS= 1.44×104 and
αPS= 0.713 (Mw > 16,700 g.mol−1) [13]. This technique allowed the
number-average molar mass (Mn), the weight-average molar mass (Mw)
and the dispersity (Mw/Mn, Ð) to be determined.
2.2.4. Dynamic light scattering (DLS) and zeta potential
Intensity-averaged nanoparticle diameters (Dz) and zeta potentials
(ζ) were measured by dynamic light scattering (DLS) with a Nano ZS
from Malvern (173° scattering angle) at a temperature of 25 °C. The
surface charge of the nanoparticles was investigated by ζ-potential
(mV) measurement at 25 °C after dilution with 1mM NaCl, using the
Smoluchowski equation.
2.2.5. Transmission electron microscopy (TEM)
The morphology of the nanoparticles was observed by TEM using a
JEOL JEM-1400 operating at 80 kV. Images were acquired using an
Orius camera (Gatan Inc., USA). 5 μL of diluted nanoparticle suspen-
sions (0.1%, v/v) were deposited for 30 s on glow-discharged copper
grids covered with formvar‑carbon film. The excess solution was blotted
off using a filter paper. Samples were then immersed for 5min in a drop
of uranyl acetate solution (2 wt%) for negative staining.
2.2.6. Electronic spin resonance (ESR)
ESR was used for the determination of the living fraction (LF) of
Gem-PI-Lap and was performed on a Bruker EMX 300 spectrometer.
Polyisoprene PI macroalkoxyamine solution ([PI]0= 1.0×10−4M) in
tert-butylbenzene (0.6mL) was prepared. The residual amount of nitr-
oxide was first determined by ESR using TEMPO solutions as external
Fig. 2. Formulation strategies to obtain polymer
prodrug nanoparticles for combination therapy from:
(a) well-defined heterotelechelic polymer prodrugs
bearing two different drugs on the same polymer
backbone, further nanoprecipitated into nano-
particles; (b) two different monofunctional polymer
prodrugs, further co-nanoprecipitated into mixed
nanoparticles and (c) a physical mixture of two dif-
ferent monofunctional polymer prodrug nano-
particles.
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standards. The solution was then heated up at 413 K for 2 h (TEMPO-
based macroalkoxyamine) in open air since dioxygen was used as ra-
dical scavenger. The solution was then analyzed by ESR and the con-
centration of the released nitroxide determined using TEMPO solutions
as external standards. The LF of the polymer was then obtained by the
difference between the nitroxide concentration after and before ther-
molysis.
2.3. Synthesis
2.3.1. Synthesis of Gem-PI-SG1
Gem-PI-SG1 was synthesized following a procedure previously
published by our group [13] and adapted as follows. Isoprene (4.1mL,
40.8 mmol) and dioxane (4.1mL) were added to Gem-AMA-SG1
(250mg, 0.408mmol) previously placed in a 15mL-capacity pressure
tube (Ace Glass 8648–164) fitted with plunger valve and a thermowell,
which then underwent three freeze-pump-thaw cycles and was even-
tually backfilled with argon. The tube was then placed in a preheated
oil bath at 115 °C for 16 h (G1 and G4) and then placed under cold
water to stop the polymerization. The volatiles were removed under
reduced pressure and the residue was precipitated in cold methanol to
give Gem-PI-SG1 as a colorless viscous oil. Other polymerizations were
performed for 16 h with [isoprene]0/[Gem-AMA-SG1]0= 200/1 (G2),
[isoprene]0/[Gem-AMA-SG1]0= 300/1 (G3) or [isoprene]0/[Gem-
AMA-SG1]0= 550/1 (G5). All purified polymers were characterized by
SEC and 1H NMR. Conversion was determined by gravimetry:
G1=34%, G2=29%, G3=26%, G4=26%, G5=14%.
2.3.2. Synthesis of PI-SG1
Isoprene (6.5mL, 65.3 mmol) and dioxane (6.5mL) were added to
AMA-SG1 (120mg, 0.327mmol) previously placed in a 15mL-capacity
pressure tube (Ace Glass 8648–164) fitted with a plunger valve and a
thermowell, which then underwent three freeze-pump-thaw cycles and
was eventually backfilled with argon. The tube then was placed in a
preheated oil bath at 115 °C for 16 h (P1) and then placed under cold
water to stop the polymerization. The volatiles were removed under
reduced pressure and the residue was precipitated in cold methanol to
give PI-SG1 as a colorless viscous oil. The purified polymer was char-
acterized by SEC and 1H NMR. Conversion was determined by gravi-
metry: P1=24%.
2.3.3. Synthesis of Gem-PI-Dox (G1D-G3D)
In a 7-mL vial were dissolved Gem-PI-SG1 (300mg, 1 eq) and
TEMPO-Dox (0.9 eq) in dry pyridine (1mL). The solution was degassed
under argon for 20min before placing the vial in a preheated oil bath at
110 °C and stirring for 16 h. Gem-PI-Dox was then precipitated two
times in cold methanol and dried under reduced pressure. The post-
functionalization yield was calculated by 1H NMR using the chemical
shifts of aromatic protons of Dox (δ=8.15, 7.79 and 7.37 ppm) and the
chemical shifts of aromatic and anomeric protons of Gem (δ=8.26,
7.48 and 6.26 ppm). The post-functionalization was also verified by UV
spectrophotometry at 480 nm (Perkin-Elmer UV/vis spectro-
photometer, Germany) and SEC equipped with a fluorescent detector
(λex= 480 nm, λem= 570 nm).
2.3.4. Synthesis of TEMPO-Lap
To a solution of succinic-TEMPO (0.47 g, 1.72mmol) and HATU
(0.79 g, 2.07mmol) in dry DMF (5mL) was added DIPEA (0.9mL,
5.20mmol) by syringe under argon atmosphere. The resulting mixture
was stirred for 30min before addition of a solution of lapatinib (1.0 g,
1.72mmol) in dry DMF (2mL). The reaction was further stirred at room
temperature for 5 h. Water was added and then extracted three times
with EtOAc. The combined organic layers were washed with brine,
dried over MgSO4 and concentrated under reduced pression. After
purification by flash chromatography (SiO2, DCM:MeOH, 98:2, v:v),
1.1 g of TEMPO-Lap were obtained, as a yellow solid. Yield: 78%. 1H
NMR (300MHz, CDCl3): δ 8.66 (s, 1H), 8.43 (s, 1H), 7.95 (d, 1H), 7.86
(d, 2H), 7.68 (m, 1H), 7.36 (m, 1H), 7.22 (m, 2H), 7.00 (t, 2H), 6.77 (d,
1H), 6.51 (d, 1H), 5.16 (s, 2H), 4.99 – 4.87 (m, 1H), 3.59 – 3.48 (m,
2H), 3.41 (t, 2H), 3.18 (m, 2H), 2.91 (m, 5H), 2.71 (t, 2H), 1.84 (m,
2H), 1.69 – 1.52 (m, 2H), 1.17 (m, 12H). MS (ESI+): m/z=836.4
(M)+. Calc. for C42H46ClFN5O8S: 835.4.
2.3.5. Synthesis of Gem-PI-Lap (G1L-G3L)
Briefly, in a 7-mL vial were dissolved Gem-PI-SG1 (300mg, 1 eq)
and TEMPO-Lap (0.9 eq) in dry pyridine (1mL). The solution was de-
gassed under argon for 20min before placing the vial in a preheated oil
bath at 110 °C and stirring for 16 h. Gem-PI-Lap was then precipitated
two times in cold methanol and dried under reduced pressure. All
purified polymers were characterized by SEC. The post-functionaliza-
tion yield was calculated by ESR and 1H NMR using the chemical shifts
of aromatic protons of Lap (δ=8.66, 8.43, 7.95, 7.86, 7.68, 7.36, 7.00,
6.77 and 6.51 ppm) and the chemical shifts of aromatic and anomeric
proton of Gem (δ=8.26, 7.48 and 6.26 ppm).
2.3.6. Synthesis of PI-Dox (D1)
PI-Dox was prepared as reported previously [29]. Briefly, in a 7-mL
vial were dissolved PI-SG1 (300mg, 1 eq) and TEMPO-Dox (0.9 eq) in
dry pyridine (1mL). The solution was degassed under argon for 20min
before placing the vial in a preheated oil bath at 110 °C and stirring for
16 h. PI-Dox was then precipitated two times in cold methanol and
dried under reduced pressure. The purified polymer was characterized
by SEC. The effectiveness of functionalization was proved qualitatively
by 1H NMR and the post-functionalization yield was measured by UV
spectrophotometry at 480 nm (Perkin-Elmer UV/vis spectro-
photometer, Germany) and SEC equipped with a fluorescent detector
(λex= 480 nm, λem=570 nm).
2.3.7. Synthesis of PI-Lap (L1)
Briefly, in a 7-mL vial were dissolved PI-SG1 (300mg, 1 eq) and
TEMPO-Lap (0.9 eq) in dry pyridine (1mL). The solution was degassed
under argon for 20min before placing the vial in a preheated oil bath at
110 °C and stirring for 16 h. PI-Lap was then precipitated two times in
cold methanol and dried under reduced pressure. The purified polymer
was characterized by SEC. The effectiveness of functionalization was
proved qualitatively by 1H NMR and the post-functionalization yield
was measured by ESR.
2.3.8. Synthesis of digly-TEMPO (2-(2-((1-oxyl-2,2,6,6-
tetramethylpiperidin-4-yl)oxy)-2-oxoethoxy)acetic acid)
A solution of 4-hydroxy-TEMPO (1.0 g, 5.80mmol), diglycolic an-
hydride (1.68 g, 14.5 mmol) and triethylamine (4.04mL, 29.0 mmol) in
DCM (20mL) was stirred 4 h at room temperature under argon atmo-
sphere. The mixture was then washed with 1M HCl and brine before
being dried over MgSO4. The residue was concentrated under reduced
pressure to give 1.30 g of Digly-AMA-SG1 as a sticky solid.
Yield= 77%. 1H NMR (300MHz, CDCl3): δ 5.20 (m, 1H), 4.18 (s, 2H),
4.11 (s, 2H), 2.18 (d, 2H), 1.99 (t, 2H), 1.41 (s, 6H), 1.37 (s, 6H). MS
(ESI-): m/z=288.2 (M)+. Calc. for C13H22NO6: 288.1.
2.3.9. Synthesis of TEMPO-digly-Dox
To a solution of digly-TEMPO (0.45 g, 1.56mmol) and HATU
(0.71 g, 1.87mmol) in dry DMF (5mL) was added DIPEA (0.8mL,
4.68mmol) by syringe under argon atmosphere. The resulting mixture
was further stirred for 30min before addition of a solution of
doxorubicin·HCl (0.91 g, 1.56mmol) in dry DMF (2mL). The reaction
was stirred at room temperature for 4 h. Water was added (50mL) and
then extracted three times with EtOAc. The combined organic layers
were washed with brine, dried over MgSO4 and concentrated under
reduced pression. After purification by flash chromatography (SiO2,
DCM:MeOH, 98:2, v:v), 0.37 g of TEMPO-digly-Dox were obtained as a
red-orange solid. Yield: 31%. 1H NMR (300MHz, CDCl3): δ 8.04 (d,
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1H), 7.80 (t, 1H), 7.41 (d, 1H), 6.11 (b, 1H), 5.54 (s, 1H), 5.31 (s, 1H),
5.05 – 4.98 (m, 1H), 4.78 (s, 2H), 4.72 – 4.62 (m, 1H), 4.22 (s, 2H), 4.14
(s, 2H), 4.09 (s, 3H), 3.70 (s, 1H), 2.39 (m, 2H), 2.18 (m, 2H), 2.03-1.75
(m, 6H), 1.51 (s, 3H), 1.48 (s, 12H). MS (ESI+): m/z=836.6
(M+Na)+. Calc. for C40H49N2O16: 813.31.
2.3.10. Synthesis of TEMPO-digly-Lap
To a solution of digly-TEMPO (0.22 g, 0.76mmol) and HATU
(0.35 g, 0.91mmol) in dry DMF (5mL) was added DIPEA (0.4mL,
2.28mmol) by syringe under argon atmosphere. The resulting mixture
was stirred for 30min before addition of a solution of Lap (0.44 g,
0.76mmol) in dry DMF (2mL). The reaction was further stirred at room
temperature for 4 h. Water was added (50mL) and then extracted three
times with EtOAc. The combined organic layers were washed with
brine, dried over MgSO4 and concentrated under reduced pression.
After purification by flash chromatography (SiO2, DCM:MeOH, 96:4,
v:v), 0.32 g of TEMPO-digly-Lap were obtained, as a yellow solid. Yield:
50%. 1H NMR (300MHz, CDCl3): δ 8.69 (s, 1H), 8.43 (s, 1H), 7.91 (q,
3H), 7.71 (d, 1H), 7.37 (m, 1H), 7.24 (m, 2H), 7.01 (m, 2H), 6.76 (s,
1H), 6.52 (s, 1H), 5.16 (s, 2H), 4.99 – 4.87 (m, 1H), 4.75 (s, 2H), 4.51
(s, 2H), 3.73 – 3.62 (m, 2H), 3.50 – 3.35 (m, 2H), 2.99 (m, 5H), 1.90 (m,
2H), 1.71 (m, 2H), 1.23 (m, 12H). MS (ESI+): m/z=851.3 (M)+. Calc.
for C42H46ClFN5O9S: 850.3.
2.3.11. Synthesis of Gem-PI-digly-Dox (G4dD, G5dD)
In a 7-mL vial were dissolved Gem-PI-SG1 (300mg, 1 eq) and
TEMPO-digly-Dox (1 eq) in dry pyridine (1mL). The solution was de-
gassed under argon for 20min before placing the vial in a preheated oil
bath at 110 °C and stirring for 16 h. Gem-PI-digly-Dox was then pre-
cipitated two times in cold methanol and dried under reduced pressure.
The post-functionalization yield was calculated by 1H NMR using the
chemical shifts of aromatic protons of Dox (δ=8.15, 7.79 and
7.37 ppm) and the chemical shifts of aromatic and anomeric proton of
Gem (δ=8.26, 7.48 and 6.26 ppm). The post-functionalization was
also verified by SEC equipped with a fluorescent detector
(λex= 480 nm, λem= 570 nm).
2.3.12. Synthesis of Gem-PI-digly-Lap (G1dL, G3dL)
In a 7-mL vial were dissolved Gem-PI-SG1 (300mg, 1 eq) and
TEMPO-digly-Lap (1 eq) in dry pyridine (1mL). The solution was de-
gassed under argon for 20min before placing the vial in a preheated oil
bath at 110 °C and stirring for 16 h. Gem-PI-digly-Lap was then pre-
cipitated two times in cold methanol and dried under reduced pressure.
All purified polymers were characterized by SEC. The post-functiona-
lization yield was calculated by 1H NMR using the chemical shifts of
aromatic protons of Lap (δ=8.66, 8.43, 7.95, 7.86, 7.68, 7.36, 7.00,
6.77 and 6.51 ppm) and the chemical shifts of aromatic and anomeric
proton of Gem (δ=8.26, 7.48 and 6.26 ppm).
2.4. Nanoparticle preparation
All nanoparticles were prepared by the nanoprecipitation technique
[72]. For P1, G2, G4dD, G5dD, G1dL or G3dL, 2.5mg of the corre-
sponding polymer prodrug were dissolved in 0.5mL of THF and quickly
added to 1mL of MilliQ water. For L1, 2 mg of polymer prodrug were
dissolved in 5mL of THF and quickly added to 10mL of MilliQ water.
The resulting nanoparticles (L1) where then subjected to a x10 con-
centration under reduced pressure. For D1, G1D, G2D, G3D, G2coD1,
G1L, G2L, G3L and G2coL1, 1 mg of the corresponding polymer pro-
drug was dissolved in 0.5mL of THF and quickly added to 1mL of
MilliQ water. For co-nanoprecipitations, the ratio between the different
polymer prodrugs was 1:1 (mol:mol). THF was evaporated at ambient
temperature using a Rotavapor. Intensity-averaged diameter (Dz) and
zeta potential measurements were carried out in triplicate by DLS. The
nanoparticle colloidal stability was assessed in water for 30 days. The
nanoparticles were kept at 4 °C and allowed to reach room temperature
before each measurement.
2.5. Gemcitabine release
Gem release kinetics was determined by using the following pro-
tocol. 0.2 mL of each nanoparticle suspension (G2, G2D, G2coD1,
G5dD, G2L, G2coL1 or G3dL) were added to 0.8 mL of human serum
supplemented with 200 μg.mL−1 tetrahydrouridine (THU) [20,73]. The
mixture was aliquoted (100 μL), incubated at 37 °C, withdrawn at dif-
ferent time points (1, 2, 4, 8 and 24 h), spiked with 10 μL of 10 μM
theophylline (Internal Standard, IS) before addition of 1mL of a mix-
ture of acetonitrile:methanol (90:10, v:v) and ultracentrifugated
(15,000 g, 20min, 4 °C). The supernatant was then evaporated to dry-
ness under a nitrogen flow at 30 °C and the released drug was quantified
by reverse-phase HPLC. The chromatographic system was composed of
a Waters 1525 Binary HPLC pump, a Waters 2707 Autosampler, a C18
Uptisphere column (3 μm, 150×4.6mm; Interchim), HPLC column
temperature controllers (model 7950 column heater and chiller; Jones
Chromatography, Lakewood, CO) and a Waters 2998 programmable
photodiode-array detector. The HPLC column was maintained at 30 °C
and detection was monitored at 270 nm. The HPLC mobile phase was a
mixture of methanol:water with 0.05M sodium acetate (pH 5.0, eluent
A: 5:95, v:v; eluent B: 97:3, v:v). The residues were dissolved in 100 μL
of eluent A. Elution was performed at a flow rate of 0.8mL.min−1
isocratically for 8min with eluent A followed by a linear gradient
(1min) to 75% eluent A and kept isocratically for 6min at 75% eluent
A. A linear gradient (1min) to 100% eluent B was followed by 10min of
isocratic gradient at 100% eluent B. After a linear gradient (1min) to
100% eluent A, the system was held for 7min for equilibration back to
initial conditions.
2.6. Cell lines and cell culture
Human breast cancer cell line MCF-7 was obtained from the
American Type Culture Collection (ATCC) and maintained as re-
commended. Briefly, MCF-7 cells were grown in Eagle's Minimum
Essential Medium (EMEM), supplemented with 10% heat-inactivated
FBS (56 °C, 30min), penicillin (100 U.mL−1) and streptomycin
(100 μg.mL−1), 1% non-essential amino acids (NEAA) and 5mL gluta-
mine. Cells were maintained in a humid atmosphere at 37 °C with 5%
CO2.
2.7. In vitro anticancer activity
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide] assay was used to evaluate the cytotoxicity of the different
polymer prodrug nanoparticles. Cells (5× 103 per well) were seeded in
96-well plates. After an overnight incubation, cells were exposed to a
series of increasing concentrations of polymer prodrug nanoparticles,
control polymers or free drugs for 72 h. Note that for dual functiona-
lized polymer prodrug nanoparticles, the concentration refers to the
concentration of each drug. At the end of the exposure time, 20 μL of
MTT solution (5mg.mL−1 in PBS) were then added in each well. Plates
were incubated for 1 h at 37 °C followed by removal of the medium and
addition of 200 μL of DMSO to each well to dissolve the formazan
crystals. Absorbance was measured at 570 nm using a plate reader
(Metertech Σ 960, Fisher Bioblock, Illkirch, France). The percentage of
surviving cells was calculated as the absorbance ratio of treated to
untreated cells. The inhibitory concentration 50% (IC50) of the treat-
ments was determined from the dose-response curve. All experiments
were repeated at least three times (6 replicates per condition) to de-
termine means and SDs. A Student's t-test was used to determine sta-
tistical differences.
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Scheme 1. (a) Synthesis of succinic-TEMPO and digly-TEMPO. (b) Synthesis of TEMPO-R-Dox and TEMPO-R-Lap. (c) Synthesis of heterobifunctional Gem-PI-R-Dox
and Gem-PI-R-Lap polymer prodrugs by “drug-initiated” nitroxide-mediated polymerization (NMP) of isoprene from Gem-AMA-SG1 followed by nitroxide exchange
from TEMPO-R-Dox and TEMPO-R-Lap. PI= polyisoprene, Gem=gemcitabine, Dox= doxorubicin and Lap= lapatinib.
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3. Results and discussion
3.1. Design rationale
The synthesis of heterotelechelic Gem/Lap and Gem/Dox polymer
prodrugs proceeded according to the polymerization of isoprene from a
SG1-containing, Gem-bearing alkoxyamine initiator for NMP, followed
by SG1 exchange reaction by a Dox- or Lap-bearing TEMPO nitroxides
to yield Gem-PI-Dox and Gem-PI-Lap, respectively (Scheme 1). PI was
selected for its biocompatibility and safety, as already demonstrated
both in vitro and in vivo [13,17,20,29]. Among the different post-
functionalization strategies that can be applied to NMP-derived poly-
mers (i.e., end-capped by a nitroxide) [23], the nitroxide exchange
reaction has been selected for its simplicity and feasibility [30]. It
consists in a thermally-governed replacement of the nitroxide at the
chain-end by a free nitroxide of different nature, driven by the estab-
lishment of a less labile polymer-nitroxide (i.e., macroalkoxyamine)
bond. The advantages of this methodology lied in: (i) the absence of
catalyst, other reactants or by-products except the released nitroxide;
(ii) a simple workup; (iii) very high/quantitative yields allowing stoi-
chiometric amounts of free nitroxide to be used and (iv) the use of
functional free nitroxides to provide easy access to end-functional
materials.
From now on, the different nanoparticles will be abbreviated as
follows (with x=1–5): PI-SG1 (Px), Gem-PI (Gx), PI-Dox (Dx), Gem-PI-
Dox (GxD), PI-Lap (Lx), Gem-PI-Lap (GxL), Gem-PI-digly-Dox (GxdD)
and Gem-PI-digly-Lap (GxdL). Polymer prodrug nanoparticles obtained
by co-nanoprecipitation of G2 and L1 (or D1) will be abbreviated as
G2coL1 (or G2coD1). Mixture of monofunctional polymer prodrug
nanoparticles G2 and L1 (or D1) will be abbreviated as G2+L1 (or
G2+D1).
3.2. Polymer prodrug synthesis
Gem was first covalently linked to the AMA-SG1 alkoxyamine to
give Gem-AMA-SG1. Then, it served as initiator/controlling agent for
the NMP of isoprene to yield a small library of α-functionalized Gem-PI
(G1-G3), obtained by varying the monomer/initiator molar ratio. Well-
controlled Gem-bearing polymers were obtained as Mn values (SEC),
varying from 1930 to 3840 g.mol−1 with low dispersities
(Đ=1.18–1.33). Given the low Mn, it resulted in high drug loadings up
to nearly 14wt% (Scheme 1c and Table 1). Note that the drug-loading
could be further increased if needed just by decreasing the PI chain
length, which is readily achievable by using RDRP.
Heterotelechelic polymer prodrugs were then obtained by the nitr-
oxide exchange reaction from a functional TEMPO nitroxide bearing the
second drug of interest. To this end, succinic-TEMPO was linked, by
HATU coupling, to Dox and Lap to give TEMPO-Dox (45% yield) or
TEMPO-Lap (78% yield), respectively (Scheme 1b). The nitroxide ex-
change reaction was then performed in pyridine at 110 °C to post-
functionalize G1-G3 into Gem-PI-Dox (G1D-G3D) or Gem-PI-Lap (G1L-
G3L) as shown in Scheme 1c and Table 1. Considering the LF of Gem-PI-
SG1 is ~80mol% [29], only 0.9 eq of functionalized TEMPO was used
to facilitate the purification of the heterobifunctional polymer. The
nitroxide exchange reaction was monitored by SEC and 1H NMR. Nearly
perfect overlays of the SEC traces (DRI detector) of Gem-PI prodrugs
G1-G3 with those of the resulting heterobifunctional prodrugs G1D-
G3D and G1L-G3L indicated that no or marginal occurrence of side/
termination reactions happened during the nitroxide exchange (Figs. 3a
and S1). Moreover, by using the intrinsic fluorescence of Dox, SEC
traces of G1D-G3D using a fluorescence detector exhibited similar
molar mass distributions than their DRI traces, thus indicating homo-
geneous chain-end functionalization by TEMPO-Dox (Figs. 3b and S2).
1H NMR was used to quantify the amount of Dox and Lap present at
the polymer chain-end (Figs. 4 and 5). The aromatic peaks of Dox
(δ=8.15, 7.79 and 7.37 ppm) and Lap (δ=8.66, 8.43, 7.95, 7.86,
7.68, 7.36, 7.00, 6.77 and 6.51 ppm) were compared to the aromatic
and anomeric peaks of Gem (δ=8.26, 7.48 and 6.26 ppm) to calculate
the yields of the nitroxide exchange reaction, which were almost
quantitative in all cases (100–92mol%). This indicates a nearly 1:1
(mol:mol) ratio between Gem/Lap and Gem/Dox. The completeness of
the reaction was also supported by the total disappearance of the proton
signal related to the proton in α position to the phosphorous atom of the
SG1 nitroxide (3.2–3.4 ppm).
Electron spin resonance (ESR) has proved to be a suitable technique
to study the nitroxide exchange reaction [29]. Therefore, ESR was used
to measure the amount of released TEMPO-Lap from Gem-PI-Lap after
heating at 413 K for 2 h. The molar fraction of released TEMPO-Lap was
found to be ~59–64mol% from G1L–G3L, which gave ~74–80mol%
coupling efficiency after taking into account the living fraction of Gem-
PI-SG1 (~80mol%) [29]. Note that the discrepancy between 1H NMR
and ESR in the determination of Lap contents may be assigned to the
relative inaccuracy in the determination of Mn values that are required
for ESR conversely to 1H NMR that does not rely on any calibration. ESR
also confirmed high purity of Gem-PI-Lap as no signal of free nitroxide
was found; neither SG1 or TEMPO before heating nor free SG1 after
Table 1
Macromolecular and structural properties of Gem-PI (Gx), Gem-PI-Dox (GxD) and Gem-PI-Lap (GxL) polymer prodrugs (x= 1–3).
Prodrug Mn,SECa (g.mol−1) Ða Mn,NMR (g.mol−1) DPn,NMRe Dox/Gemf Lap/Gemf Total drug loading (wt%)g Laph (mol.%) Doxi (mol.%)
G1 1930 1.33 1830b 18 – – 13.6 – –
G2 2880 1.20 2450b 27 – – 9.1 – –
G3 3840 1.18 2940b 34 – – 6.8 – –
G1D 2210 1.38 3190c 30 1.08 – 36.5 – 65
G2D 3210 1.24 3800c 40 1.06 – 25.1 – 62
G3D 4090 1.23 4410c 48 1.02 – 19.7 – 62
G1L 2100 1.29 2760d 24 – 0.96 40.2 64 –
G2L 3060 1.19 4020d 42 – 0.92 27.6 60 –
G3L 3890 1.18 4970d 56 – 0.93 21.7 59 –
a Determined by SEC, calibrated with PS standards and converted into PI by using Mark-Houwink-Sakurada parameters.
b Calculated according to Mn,NMR= (DPn,NMR×MWisoprene)+MWGem-AMA-SG1.
c Calculated according to Mn,NMR= (DPn,NMR×MWisoprene)+MWGem-AMA-SG1 – MWSG1+MWTEMPO-Dox.
d Calculated according to Mn,NMR= (DPn,NMR×MWisoprene)+MWGem-AMA-SG1 – MWSG1+MWTEMPO-Lap.
e Calculated from ratio of areas under the peak at 6.1–6.3, 7.3–7.5, 8.0–8.2 ppm (aromatic and anomeric proton of Gem) and 5.0–5.5 ppm (vinylic H in isoprene
repeat unit (1,4-addition), corresponding to ~81% of total isoprene units).
f Calculated by 1H NMR (see experimental part).
g Calculated according to MWGem/Mn,SEC (G1–G3), (MWGem+MWDox)/Mn,SEC (G1D–G3D) and (MWGem+MWLap)/Mn,SEC (G1L–G3L).
h Determined by ESR.
i Determined by UV spectroscopy.
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dissociation (Fig. S3). It was however not possible to have a reliable and
thus accurate quantification of the exchange conversion by ESR from
Gem-PI-Dox, likely because the quinone ring of Dox acted as a radical
scavenger. The coupling of TEMPO-Dox was alternatively measured by
UV spectroscopy based on a calibration curve using free Dox. The
amount of Dox was also found in the 62–65mol% range, which gave
78–81mol% coupling efficiency.
The nitroxide exchange reaction was also used to synthesize
monofunctional polymer prodrugs used as control polymers: PI-Dox
(D1) and PI-Lap (L1) were obtained from the reaction between PI-SG1
(P1) and TEMPO-Dox or TEMPO-Lap, respectively (Table 2). Dis-
persities of the resulting prodrugs stayed low (1.12–1.22) and their SEC
traces compared to that of the polymer precursor did not reveal sig-
nificant change in the molar mass distributions (Fig. S4a). Also, com-
parison between DRI and fluorescence traces indicated homogeneous
chain-end functionalization by TEMPO-Dox moieties (Fig. S4b). 1H
NMR spectroscopy only served to qualitatively prove the presence of
Dox and Lap at the polymer chain-end, but not quantitatively to de-
termine the nitroxide exchange reaction yield because of lack of sui-
table protons in α-position to the polymer (Figs. S5 and S6).
Nonetheless, the amount of Lap linked to the polymer was determined
by ESR showing 75% coupling yield, whereas UV spectroscopy gave
65% functionalization yield for Dox, which is in line with the other
Dox-functionalized polymers. Given the low Mn and the molecular
weights of the drugs, drug loadings of 17 and 19wt% were obtained for
D1 and L1, respectively.
To establish the versatility of the synthetic approach and potentially
to increase the drug release kinetics (and therefore the cytotoxicity), a
diglycolate linker, known to be more labile than a simple ester or amide
bond [17,20,21,74], was positioned in between TEMPO and Dox (or
Lap). The synthetic route was identical to that used previously except
hydroxy-TEMPO was reacted with diglycolic anhydride instead of
succinic anhydride to give digly-TEMPO with a 77% yield (Scheme 1a).
It was then functionalized with Dox and Lap via HATU coupling to give
TEMPO-digly-Dox and TEMPO-digly-Lap, with 31 and 50% yield, re-
spectively (Scheme 1b). Gem-PI-digly-Dox G4dD and G5dD, only dif-
fering for their Mn, were successfully obtained by reacting TEMPO-
digly-Dox with Gem-PI-SG1 G4 and G5, respectively (Scheme 1c and
Table S1). Gem-PI-digly-Lap G1dL and G3dL were similarly obtained
by reacting TEMPO-digly-Lap on G1 and G3, respectively (Scheme 1c
Fig. 3. Size exclusion chromatograms (CHCl3 eluent,
1 mL.min−1) of (a) Gem-PI-SG1 (G3, black dashed
line), Gem-PI-Dox (G3D, red dashed line) and Gem-
PI-Lap (G3L, green dashed line) and (b) Gem-PI-Dox
(G3D) fluorescence (purple dashed line) and DRI
(black dashed line) after nitroxide exchange (the gap
in retention volume between DRI and fluorescence
traces comes from the tubing between the two de-
tectors). (For interpretation of the references to
colour in this figure legend, the reader is referred to
the web version of this article.)
Fig. 4. Representative 1H NMR spectrum in CDCl3 in the 1–8.5 ppm region of (a) Gem-PI-SG1 (G2) and (b) Gem-PI-Dox (G2D), with R= succinate. After nitroxide
exchange with TEMPO-Dox, the proton signals from Dox (orange areas) appeared, those from Gem are retained (purple areas) and those from SG1 (blue area)
disappeared. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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and Table S1). Polymer prodrug characterizations by SEC (Fig. S7) and
1H NMR (Figs. S8 and S9) confirmed the formation of the expected
structures.
3.3. Nanoparticle formulation and colloidal properties
Bare (drug-free), monofunctional and heterobifunctional polymer
(prodrug) nanoparticles were obtained by nanoprecipitation of the re-
spective polymers in water without any surfactant (Table 3). All types
of nanoparticles showed small average diameters and narrow particle
size distributions (PSD). Moreover, the surface charges of all nano-
particles were strongly negative, which is usually a premise of an effi-
cient colloidal stability. Bare nanoparticles were 118 nm in diameter,
while monofunctional prodrug nanoparticles were much smaller
(Dz= 49–68 nm), likely because of an increased amphiphilicity of the
polymer after its coupling to the drug. Mixed polymer prodrug nano-
particles G2coD1 and G2coL1 had a larger average diameter of 91 and
192 nm, respectively.
Interestingly, heterotelechelic polymer prodrug nanoparticles G1D-
G3D exhibited very small diameters around 40 nm, likely because of π-
π stacking interactions between Dox molecules, leading to more packed
nanoparticles. For the first time, nanoparticles containing the Gem/Lap
combination (G1L-G3L) were formulated. They presented an average
diameter ranging from 73 to 154 nm with no correlation between the
polymer molar mass and the nanoparticle size. The nanoparticles were
also analyzed by TEM, showing spherical morphologies and size in
Fig. 5. Representative 1H NMR spectrum in CDCl3 in the 1–9 ppm region of (a) Gem-PI-SG1 (G2) and (b) Gem-PI-Lap (G2L), with R= succinate. After nitroxide
exchange with TEMPO-Lap, the proton signals from Lap (orange areas) appeared, those from Gem are retained (purple areas) and those from SG1 (blue area)
disappeared. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 2










P1 2860 1.13 – – –
D1 3220 1.22 16.7 – 65
L1 3060 1.12 19.0 75 –
a Determined by SEC, calibrated with PS standards and converted into PI by
using Mark-Houwink-Sakurada parameters.
b Calculated according to MWDox/Mn,SEC (D1) and MWLap/Mn,SEC (L1).
c Determined by ESR.
d Determined by UV spectroscopy.
Table 3
Characterization of Gem-PI (Gx), Gem-PI-Dox (GxD), PI-Dox (Dx), Gem-PIcoPI-
Dox (G2coD1), Gem-PI-Lap (GxL), PI-Lap (Lx) and Gem-PIcoPI-Lap (G2coL1)
prodrug nanoparticles (x= 1–3).









P1 118 ± 2 0.14 −29 – – – –
G2 68 ± 1 0.13 −29 9.1 – – 9.1
D1 66 ± 2 0.15 −44 – 16.9 – 16.9
L1 49 ± 3 0.12 −36 – – 19.0 19.0
G1D 34 ± 3 0.22 −32 11.9 24.6 – 36.5
G2D 43 ± 2 0.16 −35 8.2 16.9 – 25.1
G3D 37 ± 1 0.14 −24 6.4 13.3 – 19.7
G2coD1 91 ± 2 0.13 −41 4.3 8.9 – 13.2
G1L 73 ± 1 0.03 −23 12.5 – 27.7 40.2
G2L 154 ± 3 0.01 −27 8.6 – 19.0 27.6
G3L 103 ± 1 0.04 −29 6.8 – 14.9 21.7
G2coL1 192 ± 4 0.17 −47 4.4 – 9.8 14.2
a Measured by dynamic light scattering (DLS). Nanoparticle concentration
was: 2.5 mg.mL−1 for P1, G2, G4dD, G5dD, G1dL, G3dL; 1 mg.mL−1 for D1,
G1D–G3D, G2coD1, G1L–G3L and G2coL1, and 2mg.mL−1 for L1.
b Calculated according to MWGem/Mn,SEC.
c Calculated according to MWDox/Mn,SEC.
d Calculated according to MWLap/Mn,SEC.
D. Vinciguerra et al. Journal of Controlled Release 295 (2019) 223–236
231
agreement to those determined by DLS (Fig. 6a and b).
An important characteristic of heterotelechelic polymers is the
ability to yield high drug loading nanoparticles. Here nanoparticles
embedding two drugs reached a total DL ranging from ~20wt% up to
~40wt%, which is much higher than traditional drug-loaded nano-
particles and most of polymer-prodrug nanoparticles. Also, formulation
of heterobifunctional polymer prodrugs is much advantageous in terms
of DL than the co-nanoprecipitation of monofunctional polymer pro-
drugs because more polymer is needed in the latter case to reach an
equivalent dose of drugs, thus lowering the DL.
The long-term colloidal stability of Gem/Dox and Gem/Lap nano-
particles was monitored in water (Fig. 6c and d, respectively). Gem-PI-
Dox (G2D and G3D) and G2coD1 nanoparticles were stable over
15 days whereas G1D was stable up to 7 days. The less efficient stability
of G1D could be attributed to the modified hydrophilic-lipophilic bal-
ance because of the shorter polymer chain. Gem-PI-Lap (G1L-G3L) and
G2coL1 nanoparticles were all stable over more than one month. In-
terestingly, heterobifunctional polymer prodrugs G1L-G3L showed a
decrease in diameter within the first 10 days before exhibiting constant
average diameters, suggesting slow rearrangement over time of the
polymer prodrugs within the nanoparticles.
Similarly, diglycolate-containing heterobifunctional polymer pro-
drugs, Gem-PI-digly-Dox (G4dD and G5dD) and Gem-PI-digly-Lap
(G1dL and G3dL), were formulated into nanoparticles with average
diameters in the 46–149 nm range (Table S2).
3.4. In vitro gemcitabine release
Amide bonds are stable in water but can be cleaved for instance by
cathepsin [75], that are present in higher concentrations in lysosomes
of tumor cells. The in vitro release of Gem from the different prodrug
nanoparticles was monitored over time at 37 °C in pure human serum,
to mimic the biological environment. Monofunctional Gem-PI (G2)
nanoparticles showed a Gem release of 6.1 mol% after 24 h. Gem-PI-
coPI-Dox (G2coD1) nanoparticles had a slightly higher Gem release
than G2 reaching 8.2 mol%. Conversely, heterobifunctional polymer
prodrug nanoparticles Gem-PI-Dox (G2D) and Gem-PI-diglyDox
(G5dD) had much slower Gem release kinetics than G2, leading to 1.6
and 1.9mol% after 24 h (Fig. 7a). Importantly, nanoparticles con-
taining Lap instead of Dox showed the same trends: Gem-PIcoPI-Lap
(G2coL1) gave 8.3 mol% of released Gem, whereas heterobifunctional
Gem-PI-Lap (G2L) and Gem-PI-digly-Lap (G3dL) nanoparticles both led
to< 1mol% of Gem released (Fig. 7b).
Moreover, all Gem release kinetics from monofunctional polymer
prodrug nanoparticles rapidly reached a plateau within the first few
hours. It suggested that, at least during the first 24 h, only surface-ex-
posed Gem was able to be efficiently cleaved by enzymes [16] because
the high colloidal stability of the nanoparticles prevented the drug
buried in the nanoparticle core to be rapidly cleaved off the polymer.
Such a significant difference in the Gem release pattern between het-
erobifunctional polymer prodrug nanoparticles and monofunctional
counterparts (either prepared from Gem-PI alone or resulting from their
co-nanoprecipitation with another monofunctional polymer prodrug)
might be assigned to a change in the supramolecular organization of the
polymer chains during the nanoparticle formation. Indeed, given the
low Mn of the polymer and the different solubility of drugs (Gem is
hydrophilic whereas Lap or Dox are hydrophobic), placement of Gem
within, and at the surface of the nanoparticles, may be shifted toward
the core of the nanoparticles when another drug is attached at the
chain-end.
Surprisingly, we were not able to detect any release of Dox or Lap,
regardless of the nature of the linker (i.e., succinate or diglycolate). This
observation was at first glance unexpected since the diglycolate linker
was supposed to promote the release of Lap (G3dL) and Dox (G5dD), as
Fig. 6. Representative TEM images of (a) Gem-PI-
Dox nanoparticles G3D (scale bar= 1 μm) and (b)
Gem-PI-Lap nanoparticles G2L (scale bar= 0.5 μm).
Evolution of the average diameters (Dz) and the
particle size distributions (PSD) measured by DLS in
water of (c) Gem-PI-Dox nanoparticles (G1D, G2D,
G3D and G2coD1) and (d) Gem-PI-Lap nanoparticles
(G1L, G2L, G3L and G2coL1).
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previously shown for other types of monofunctional polymer prodrug
nanoparticles [16,17,20,21]. However, since Lap and Dox are both
hydrophobic and likely localized into the core of the nanoparticles,
their absence of release further confirmed the high colloidal stability of
the nanoparticles (at least under the conditions and within the time
frame of the drug release experiments), that prevented enzyme access
and/or colloidal disassembly. Note also that in vitro experiments may
not fully reflect the complexity of an in vivo tumor model, whose
conditions (e.g., acidic pH in the tumor microenvironment, higher
concentrations of specific enzymes, etc.) may contribute to induce a
faster colloidal disassembly of the nanoparticles and thus a more sig-
nificant drug release.
3.5. In vitro cell viability
The two series of heterobifunctional polymer prodrug nanoparticles,
Gem-PI-Dox and Gem-PI-Lap, were tested for their cytotoxicity on
human breast cancer cell line MCF-7, a model widely used to test these
drugs and their combinations [41,52,53,57,58]. Given the high cou-
pling efficiencies from ESR/UV measurements and the quantitative
coupling efficiencies from 1H NMR, equimolar drug ratios were con-
sidered for heterobifunctional polymer nanoparticles and nanoparticles
combining both drugs. To determine the best way to transport and
deliver a prodrug combination from nanocarriers, other formulation
options were tested, such as the co-nanoprecipitation of monofunctional
polymer prodrugs and the mixture of the two monofunctional polymer
prodrug nanoparticles. Also, control formulations composed of mono-
functional polymer prodrug nanoparticles from each drug were tested.
The cells were incubated with increasing concentrations of the different
prodrug nanoparticles or free drugs for 72 h to determine the IC50.
First, bare (i.e., drug-free) PI nanoparticles were not cytotoxic on
MCF-7 cells up to at least 2.5 μM; that is higher than the concentrations
of the different prodrugs, thus excluding potential cytotoxicity of the
vehicle (Fig. S10).
Regarding Gem/Dox combination (Fig. 8), free Dox led to an IC50 of
92 nM, whereas IC50 of free Gem and its 1:1 combination with Dox was
as low as 7 and 6 nM, respectively (Table 4), showing the higher cy-
totoxicity of Gem compared to Dox on this cancer cell line. Also, no
synergy was obtained for the combination of free drugs.
Second observation is that both monofunctional prodrug nano-
particles were less active than the corresponding free drugs
(IC50= 1.89 μM and 53 nM for D1 and G2, respectively), which is
somewhat expected since the drug needs to get cleaved off the polymer
before regaining its activity. Also, free drugs are not (or poorly) sub-
jected to early metabolization and degradation in vitro, hence ex-
hibiting optimal cytotoxicity, conversely to in vivo where using
prodrugs takes on its full meaning (especially with Gem).
Heterobifunctional Gem-PI-Dox nanoparticles gave decreasing IC50
values with the increase of the Mn, as IC50= 288, 221 and 121 nM for
G1D, G2D and G3D, respectively (Table 4). This IC50 vs Mn trend has
already been observed for other types of “drug-initiated” polymer pro-
drug nanoparticles [17,21,29] and might be attributed to a better cell
uptake for higher nanoparticle surface hydrophobicity when the Gem
content is decreased. However, heterobifunctional Gem-PI-Dox
Fig. 7. Gem release profiles at 37 °C in human serum from (a) Gem-PI (G2), Gem-PIcoPI-Dox (G2coD1), Gem-PI-Dox (G2D) and Gem-PI-diglyDox (G5dD) and (b)
Gem-PI (G2), Gem-PIcoPI-Lap (G2coL1), Gem-PI-Lap (G2L) and Gem-PI-digly-Lap (G3dL).
Fig. 8. IC50 values ± SD of Gem-PI-Dox (G1D-G3D), Gem-PI (G2), PI-Dox
(D1), Gem-PIcoPI-Dox (G2coD1), Gem-PI+PI-Dox (G2+D1) nanoparticles,
free Gem, free Dox and free Gem+Dox (1:1, mol:mol) determined by MTT test
on MCF-7 cells after 72 h of incubation. (*p < 0.05, G2+D1, G2 vs G2coD1).
Table 4
Half maximal inhibitory concentrations (IC50) of free drugs (Gem, Dox, Lap,
Gem+Lap, Gem+Dox), prodrug nanoparticles [Gem-PI (G2), Gem-PI-Dox
(G1D-G3D), PI-Dox (D1), Gem-PIcoPI-Dox (G2coD1), Gem-PI-Lap (G2L-G3L),
PI-Lap (L1) and Gem-PIcoPI-Lap (G2coL1)] and physical mixtures of nano-
particles (G2+D1 and G2+L1).
Gem/Dox formulations IC50 (nM)a Gem/lap formulations IC50 (nM)a
Gem 7 ± 2 Gem 7 ± 2
Dox 92 ± 21 Lap 6070 ± 1210
Gem+Dox 6 ± 1 Gem+Lap 5 ± 1
G2 53 ± 5 G2 54 ± 3
D1 1890 ± 720 L1 152 ± 40
G2+D1 53 ± 3 G2+L1 44 ± 13
G2coD1 64 ± 4 G2coL1 33 ± 5
G1D 288 ± 77 G2L 214 ± 146
G2D 221 ± 48 G3L 282 ± 47
G3D 121 ± 38
a Expressed as IC50 ± SD determined by MTT test after 72 h of incubation
on MCF7 cells.
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nanoparticles G1D–G3D were more cytotoxic than prodrug nano-
particles D1, but less than prodrug nanoparticles G2 and monofunc-
tional prodrugs either used as mixed formulations (G2+D1,
IC50= 53 nM) or resulting from a co-nanoprecipitation (G2coD1,
IC50= 64 nM). This result is in line with the drug release study reported
in Fig. 7a, showing that release of Gem is much slower when Dox is
attached at the other polymer chain-end. Replacing the succinate linker
by a supposedly more labile diglycolate linker did not improve the
cytotoxicity pattern (Fig. S11a), which is in agreement with the deep
localization of Dox into the nanoparticle core and its poor accessibility
to enzymes. It thus tends to support a different placement of each drug
within the nanoparticles and its crucial role on the drug release and
eventually its activity.
Interestingly, given that nanoparticles D1 had a much higher IC50
than nanoparticles G2, the physical mixture of nanoparticles (G2+D1)
had the same cytotoxicity than nanoparticles G2. However, co-nano-
precipitated prodrugs G2coD1 led to slightly lower cytotoxicity than
nanoparticles G2 or G2+D1.
Evaluation of the Gem/Lap combination resulted in a quite different
behavior (Fig. 9). Free Lap had a much higher IC50 (6.0 μM) than any
other formulations. Interestingly, Lap-containing polymer prodrug na-
noparticles drastically improved its anticancer activity, as PI-Lap (L1)
had a much small IC50 value (152 nM). This enhancement can be as-
signed to improved solubility and therefore better cell uptake, as pre-
viously described for traditional Lap-loaded nanoparticulate systems
[39–41]. Driven by its very high cytotoxicity, not only free Gem gave a
very low IC50 (7 nM), but also its monofunctional prodrug (G2,
IC50= 54 nM), although to a lesser extent because of the prodrug
nature as explained earlier. Due to the much higher free Gem activity
compared to free Lap, the IC50 of their 1:1 combination was very similar
to the one of free Gem (5 nM), but no synergy was noticed. However,
heterotelechelic Gem-PI-Lap polymer prodrug nanoparticles led to
higher IC50 values, similar to that of L1, ranging from 214 to 282 nM for
G2L and G3L, respectively (Table 4). Again, switching from succinate
to diglycolate linker between Lap and the polymer did not provide any
benefit (Fig. S11b).
Remarkably, whereas the physical mixture G2+L1 had a com-
parable IC50 (44 nM) than G2, similarly to what has been observed with
Gem/Dox combination, the co-nanoprecipitated formulation (G2coL1)
presented a lower IC50 than G2 (33 nM), corresponding to a 39 and 78%
decrease compared to IC50 values of G2 and L1, respectively (Table 4).
Using the combination index (CI), which is a well-established method to
evaluate the combination effect [76], a synergistic effect was found for
G2coL1 (CI= 0.83), whereas the physical mixture G2+L1 led to a
simple additive effect (CI= 1.10). Therefore, co-administering Gem
and Lap into the same nanoparticle led to synergistic effect in vitro.
Nonetheless, the same effect was not present for heterotelechelic
polymer, likely because of the drastically reduced Gem release kinetics
(Fig. 7b) when Lap is attached at the other chain-end.
These findings showed that, in the context of combination therapy,
the nature/properties of each drug and the way they are transported
and organized into a nanocarrier, are of paramount importance for the
overall therapeutic efficacy. Indeed, whereas heterobifunctional
polymer prodrug nanoparticles based on Agm/Dox combination gave
synergistic effect [29], monofunctional polymer prodrug formulations
based on the Gem/Dox combination (G2 and G2coD1 and G2+D1)
were the most cytotoxic, and only co-nanoprecipitated monofunctional
Gem/Dox prodrugs G2coL1 led to synergistic effect. It therefore sug-
gested that each combination of drugs may act differently and finding
optimal conditions is a case-by-case study, that can be easily and effi-
ciently investigated through our synthetic approach.
4. Conclusion
In this work, we synthesized two different and well-defined het-
erotelechelic polymer prodrug nanoparticles for combination therapy.
The methodology was based on the “drug-initiated” method, during
which a small polymer chain was grown in a controlled fashion from
the first drug by NMP, before end-capping the polymer chain-end by a
nitroxide bearing the second drug of interest under nitroxide exchange
reaction. We successfully applied this approach to Gem/Dox and Gem/
Lap, which are combinations of high clinical relevance, and proved that
it is a robust, versatile yet simple construction methodology for drug
delivery purposes.
To highlight the importance of the way drug combinations are
transported, heterotelechelic polymer prodrug nanoparticles were
evaluated in terms of drug release and cytotoxicity together with
monofunctional polymer prodrug formulations, either independent,
physically mixed or formulated by co-nanoprecipitation. The results
revealed that the nature and properties of the selected drugs had a
tremendous effect on the outcome of the cytotoxicity, likely deriving
from different spatial organization of the different drugs within the
nanoparticles. Indeed, whereas Gem/Dox combination did not show
any improvement over monofunctional therapies, co-nanoprecipitation
of Gem/Lap prodrugs led to synergistic effect, which represents the first
nanocarrier for the delivery of Gem and Lap together.
Although the purpose of this study was not to find the best optimal
ratios between the two drugs from each combination, but rather to
show a certain degree of universality of the synthetic methodology and
to compare different formulation strategies, such further studies could
be performed by readily tuning the amounts of drugs by playing with
the nitroxide exchange reaction yield.
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